
Novo Nordisk is expecting to conclude its phase III program, dubbed Onwards, with its once-weekly insulin Icodec in 2022.
”The first data from Onwards will arrive within a couple of months, after which the results from other studies will roll in throughout the year,” says Martin Holst Lange, executive vice president of development at Novo Nordisk, in connection with the company’s capital markets day on Thursday.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app